The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS/iwMPN 2026 | Prognostication in TP53-mutated MDS: are there favorable-risk subtypes?
Tariq Kewan, MD, Mayo Clinic, Rochester, MN, discusses prognostication in TP53-mutated myelodysplastic syndromes (MDS), exploring whether certain molecular subtypes are associated with more favorable outcomes. Dr Kewan highlights the prognostic significance of TP53 allelic status, variant allele frequency (VAF), cytogenetic abnormalities, and mutation-specific functional characteristics, including their implications for survival and allogeneic stem cell transplantation. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
